IL6 and congenital rubella syndrome: By binding to IL-6R, Tocilizumab accurately inhibits the downward transmission of IL-6 signaling pathways and effectively reduces the secretion of various acute inflammatory proteins such as CRP, and is considered to be a safe drug that suppresses CRS without affecting CAR-T cell expansion and long-term remission (2, 4, 19).